Literature DB >> 26253996

Individual metatarsal and forefoot kinematics during walking in people with diabetes mellitus and peripheral neuropathy.

Frank E DiLiberto1, Josh Tome2, Judith F Baumhauer3, Jeff Houck4, Deborah A Nawoczenski5.   

Abstract

The purpose of this study was to compare in-vivo kinematic angular excursions of individual metatarsal segments and a unified forefoot segment in people with Diabetes Mellitus and peripheral neuropathy (DMPN) without deformity or ulceration to a healthy matched control group. Thirty subjects were recruited. A five- segment foot model (1st, 3rd, and 5th metatarsals, calcaneus, tibia) was used to examine relative 3D angular excursions during the terminal stance phase of walking. Student t-tests were used to assess group differences in kinematics. Pearson correlations and cross-correlations were used to assess relationships between the motion of the individual metatarsals and the unified forefoot. Significant reductions of DMPN group sagittal plane angular excursions were detected in all individual metatarsals and the unified forefoot (p < 0.01). Frontal plane 3rd metatarsal excursion was reduced (p = 0.04) in the DMPN group. The 3rd and 5th metatarsal and the unified forefoot excursions were reduced (p ≤ 0.02) in the DMPN group in the transverse plane. In both groups, coupling of individual metatarsal and unified forefoot motion was strongest in the sagittal plane. This study illustrates that multiple individual metatarsals have reduced motion in people with DMPN. Differences in the magnitude and coupling between individual metatarsal motion and unified forefoot motion supports the use of a two segment forefoot modeling approach in future kinematic analyses. Further study is recommended to determine if the observed kinematic profile is related to the development and location of deformity and tissue breakdown in people with DMPN.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; Foot kinematics; Multi-segment foot model

Mesh:

Year:  2015        PMID: 26253996     DOI: 10.1016/j.gaitpost.2015.07.012

Source DB:  PubMed          Journal:  Gait Posture        ISSN: 0966-6362            Impact factor:   2.840


  6 in total

Review 1.  Summary Report of the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society's Symposium on Targets for Osteoarthritis Research: Part 2: Treatment Options.

Authors:  Jason S Kim; Annunziato Amendola; Alexej Barg; Judith Baumhauer; James W Brodsky; Daniel M Cushman; Tyler A Gonzalez; Dennis Janisse; Michael J Jurynec; J Lawrence Marsh; Carolyn M Sofka; Thomas O Clanton; Donald D Anderson
Journal:  Foot Ankle Orthop       Date:  2022-10-14

2.  Body mass index and maximum available midfoot motion are associated with midfoot angle at peak heel rise in people with type 2 diabetes mellitus and peripheral neuropathy.

Authors:  Hyo-Jung Jeong; Michael J Mueller; Jennifer A Zellers; Paul K Commean; Ling Chen; Mary K Hastings
Journal:  Foot (Edinb)       Date:  2022-02-11

3.  Midfoot and ankle motion during heel rise and gait are related in people with diabetes and peripheral neuropathy.

Authors:  Hyo-Jung Jeong; Michael J Mueller; Jennifer A Zellers; Mary K Hastings
Journal:  Gait Posture       Date:  2020-11-16       Impact factor: 2.840

4.  The prevention of diabetic foot ulceration: how biomechanical research informs clinical practice.

Authors:  Frank E DiLiberto; Judith F Baumhauer; Deborah A Nawoczenski
Journal:  Braz J Phys Ther       Date:  2016-11-16       Impact factor: 3.377

5.  Diabetic Gait Is Not Just Slow Gait: Gait Compensations in Diabetic Neuropathy.

Authors:  Adrienne D Henderson; A Wayne Johnson; Sarah T Ridge; Jonathan S Egbert; Kevin P Curtis; Levi J Berry; Dustin A Bruening
Journal:  J Diabetes Res       Date:  2019-11-11       Impact factor: 4.011

Review 6.  Diabetic Neuropathy and Gait: A Review.

Authors:  Uazman Alam; David R Riley; Ravinder S Jugdey; Shazli Azmi; Satyan Rajbhandari; Kristiaan D'Août; Rayaz A Malik
Journal:  Diabetes Ther       Date:  2017-09-01       Impact factor: 2.945

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.